참고문헌
- Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012;2012:913848. https://doi.org/10.1155/2012/913848
- Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 2017;81:772-781. https://doi.org/10.1002/ana.24951
- Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:1941-1967. https://doi.org/10.1200/JCO.2013.54.0914
- Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007;130:1076-1088. https://doi.org/10.1093/brain/awl356
- Tzatha E, DeAngelis LM. Chemotherapy-induced peripheral neuropathy. Oncology (Williston Park) 2016;30:240-244.
- McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 2002;9:220-233. https://doi.org/10.1006/nbdi.2001.0468
- Podratz JL, Knight AM, Ta LE, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 2011;41:661-668. https://doi.org/10.1016/j.nbd.2010.11.017
- Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A 2012;109:6704-6709. https://doi.org/10.1073/pnas.1118058109
- Conde C, Caceres A. Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 2009;10:319-332. https://doi.org/10.1038/nrn2631
- Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-225. https://doi.org/10.1016/j.ejca.2016.02.024
- Johnson C, Pankratz VS, Velazquez AI, et al. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 2015;349:124-128. https://doi.org/10.1016/j.jns.2014.12.041
- Abraham JE, Guo Q, Dorling L, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res 2014;20:2466-2475. https://doi.org/10.1158/1078-0432.CCR-13-3232
- Apellaniz-Ruiz M, Lee MY, Sanchez-Barroso L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res 2015;21:322-328. https://doi.org/10.1158/1078-0432.CCR-14-1758
- Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099-5109. https://doi.org/10.1158/1078-0432.CCR-12-1590
- Boora GK, Kulkarni AA, Kanwar R, et al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 2015;357:35-40. https://doi.org/10.1016/j.jns.2015.06.056
- Chen J, Yin J, Li X, et al. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients. Int J Mol Sci 2014;15:21011-21027. https://doi.org/10.3390/ijms151121011
- Custodio A, Moreno-Rubio J, Aparicio J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 2014;25:398-403. https://doi.org/10.1093/annonc/mdt546
- Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Il-e105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006;12:3050-3056. https://doi.org/10.1158/1078-0432.CCR-05-2076
- Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer 2016;24:1439-1447. https://doi.org/10.1007/s00520-015-3063-4
- Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309:1359-1367. https://doi.org/10.1001/jama.2013.2813
- Kleckner IR, Kamen C, Gewandter JS, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019-1028. https://doi.org/10.1007/s00520-017-4013-0